Head-to-head · WeighScore
Harbor vs NewSelf
By GLP-1 ScorecardUpdated
Score comparison
NewSelf has the higher recorded score — 79.8/100 to 72/100.
NewSelf grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Round-$100 semaglutide, $144 tirzepatide, verified and available in all 50 states.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Harbor | NewSelf |
|---|---|---|
| WeighScore | 72/100 | 79.8/100 |
| Grade | C | C+ |
| Site position | #95 | #39 |
| Semaglutide | $99/mo (starting dose, compounded) | $100/mo |
| Tirzepatide | $149/mo (starting dose, compounded) | $144/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #95 · C
Strengths
- Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
- LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
- 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
- 12-Month Money Back Guarantee if you don't reach your weight-loss goal
- HSA/FSA eligible; no hidden fees, no insurance billed
What to consider
- Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
- Dietitian support offered only post-program (maintenance phase), not during active treatment
- State-specific consultation types vary; nationwide availability unconfirmed for all states
- No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
- Newer brand; success rate and member counts are on-site claims, not third-party verified
Site position #39 · C+
FDAWarning letter issued to NewSelf Limited dba NewSelf in February 2026. See the FDA warning-letter database.
Strengths
- $100 sema / $144 tirz
- All 50 states, LegitScript-verified
- Both molecules
What to consider
- Injection-only
- Labs/monitoring detail sparse
- Limited brand history
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.